How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Appraisal consultation document

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about rimegepant

Marketing authorisation indication

2.1 Rimegepant (Vydura, Pfizer) is indicated for the 'acute treatment of migraine with or without aura in adults'.

2.2 Rimegepant for preventative treatment is being evaluated in NICE's technology appraisal guidance on rimegepant for preventing migraine (ID6275).

Dosage in the marketing authorisation

2.3 The dosage schedule is available in the summary of product characteristics for rimegepant.

Price

2.4 The proposed price of rimegepant is £12.90 per 75 mg tablet (excluding VAT).